Tag: accessibility

SANTA ANA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the presentation of a poster entitled, “Mechanism of Action of Troculeucel (Non-genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) in Alzheimer's Disease Confirmed by Corresponding Phase I Biomarker Data” at the Alzheimer’s Association International Conference 2025 (“AAIC 2025”) held in Toronto, Canada and online from July 27-31, 2025.

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pony AI Inc. (“Pony.ai” or the “Company”) (Nasdaq: PONY), a global leader in achieving large-scale commercialization of autonomous mobility, today announced that it will report its unaudited financial results for the second quarter 2025 before the U.S. market opens on Tuesday, August 12, 2025.

Zurich, Switzerland, July 27, 2025 (GLOBE NEWSWIRE) -- MGPD Finance Limited, doing business as HashJ, today announced the official launch of its short-term BTC contract offerings, designed to help everyday users benefit from Bitcoin’s record-breaking rally past $118,000. The launch marks a new chapter in making digital asset participation simpler, faster, and more predictable—especially for mobile-first users worldwide.

SHANGHAI, China, July 26, 2025 (GLOBE NEWSWIRE) -- Pony AI Inc. (“Pony.ai” or the “Company”) (Nasdaq: PONY), a global leader in achieving large-scale commercialization of autonomous mobility, today announced that it has received a permit to provide fully driverless commercial Robotaxi services of Shanghai’s Pudong New Area, issued at the World Artificial Intelligence Conference (“WAIC”) 2025. This achievement demonstrates not only increasing regulatory trust and recognition in the Company’s technology and safety standards, but also represents another major milestone in advancing Robotaxi commercialization in a top-tier urban market in China.

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-12 (the “Reverse Stock Split”). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on August 5, 2025 under the existing symbol of “CLDI.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 408.